SCHEMBL7962016

SCHEMBL7962016

N#C/N=C1/CC2(CCCN(c3ccccc3)C2)Oc2ccc(-c3cccc(C#N)c3)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.37
ALDH1A1 P00352 2/20 0.37
TP53 P04637 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C9 P11712 2/20 0.37
CYP2C19 P33261 2/20 0.37
HSD17B10 Q99714 2/20 0.37
LRRK2 Q5S007 6/20 0.36
USP30 Q70CQ3 1/20 0.35
MCHR1 Q99705 1/20 0.35
PGR P06401 2/20 0.35
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
BACE1 P56817 3/20 0.34
OTUD7B Q6GQQ9 3/20 0.34
CHEK1 O14757 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7964219 0.89 BACE1 (0.38) USP2ALDH1A1TP53CYP1A2CYP3A4
SCHEMBL7950709 0.88 SLC6A7 (0.42) TP53CYP1A2CYP3A4LRRK2USP30
SCHEMBL7949753 0.87 PGR (0.44) USP2ALDH1A1TP53CYP1A2CYP3A4
SCHEMBL2375588 0.82 BACE1 (0.41) LRRK2PGRBACE1OTUD7B
SCHEMBL2375582 0.82 BACE1 (0.41) LRRK2PGRBACE1OTUD7B
SCHEMBL2392243 0.81 BACE1 (0.41) PGRBACE1OTUD7BCHEK1
SCHEMBL2392250 0.81 BACE1 (0.41) PGRBACE1OTUD7BCHEK1
SCHEMBL1820031 0.81 BACE1 (0.45) PGRBACE1OTUD7B
SCHEMBL1820029 0.81 BACE1 (0.45) PGRBACE1OTUD7B
SCHEMBL7960756 0.80 DRD2 (0.37) CYP2D6PGRTSHRBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
EP-2324032-B1 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS INC (US) 2014-10-01 EP disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed
WO-2010021680-A2 INHIBITORS OF BETA-SECRETASE VITAE PHARMACEUTICALS, INC. (US) 2010-02-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP USP2 2151/4885ALDH1A1 2484/4885TP53 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.